Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis

CD47 is a promising new target in cancer immunotherapy and recently the pro-phagocytic signal SLAMF7 has been shown to have a crucial role in phagocytosis induced by CD47-blocking antibody in hematological tumors. In this study, the authors demonstrate that SLAMF7 expressed by cancer cells is not re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yuan He, Renee Bouwstra, Valerie R. Wiersma, Mathilde de Jong, Harm Jan Lourens, Rudolf Fehrmann, Marco de Bruyn, Emanuele Ammatuna, Gerwin Huls, Tom van Meerten, Edwin Bremer
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Q
Acceso en línea:https://doaj.org/article/69bb46c6cb07419c8c3da1b05f0247bc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:CD47 is a promising new target in cancer immunotherapy and recently the pro-phagocytic signal SLAMF7 has been shown to have a crucial role in phagocytosis induced by CD47-blocking antibody in hematological tumors. In this study, the authors demonstrate that SLAMF7 expressed by cancer cells is not required for phagocytosis suggesting that, in contrast to CD47 expression, SLAMF7 should not be used as selection criterion for CD47-targeted therapy.